Full-Time
Line Servicer
Warehouse
Posted on 8/18/2026
Revance
501-1,000 employees
Biotech aesthetics company: neuromodulators and fillers
No salary listed
Johnson City, TN, USA
In Person
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Revance
See people who can refer or advise you
- A high school diploma or equivalent is required.
- Good math skills are required.
- Knowledge and experience working in a production team environment are required.
- The ability to work in a fast-paced environment is required.
- Strong problem-solving skills are required.
- Strong verbal and written communication skills are required.
- The ability to work the second shift and overtime as needed is required.
- Verify that the proper components and quantities have been staged to meet batch-production needs.
- Communicate discrepancies to minimize the possibility of downtime.
- Maintain an adequate supply of packaging components throughout the packaging operation.
- Maintain production time records for each packaging line.
- Verify that the appropriate and legible shipper label is on each shipper.
- Verify that the appropriate stacking pattern is used on each pallet.
- Move completed skids or containers of completed stock to designated areas using a pallet jack or industrial lift truck.
- Ensure that each pallet of completed production is shrink-wrapped.
- Prepare and maintain accurate documentation.
- Assist the packaging department with other assigned duties.
- Use the Ross system.
- Computer skills are highly desirable.
- A college degree is preferred.
Revance Therapeutics develops neuromodulators and dermal fillers for the premium aesthetics market, with possible therapeutic uses for muscle movement and pain disorders. Its injectable products are used by healthcare professionals to reduce wrinkles and restore facial volume, improving patient outcomes. The company stands apart by pairing a portfolio of cosmetic injectables with HintMD, a fintech platform that streamlines payments and clinic management for aesthetic practices. Its goal is to lead the premium aesthetics space by offering differentiated injectables and expanding fintech-enabled services for practice efficiency.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Nashville, Tennessee
Founded
1999
Get referred to Revance
See people who can refer or advise you
Simplify's Take
What believers are saying
- March 2026 RHA Dynamic Volume launch widened Revance's filler portfolio before Redensity Eye.
- Nadeem Moiz hired Scott Leffler and Kira Schwartz on October 1, 2025, strengthening execution.
- Janelle Wichmann's 2026 skincare appointment targets PanOxyl, Blue Lizard, and StriVectin growth.
What critics are saying
- Crown Laboratories paid $3.65 per share in 2025, signaling limited standalone strategic value.
- Revance's $17 million securities settlement finalized August 12, 2026, keeping disclosure scrutiny alive.
- Teoxane partnership concentrates filler economics; any supply dispute quickly crushes RHA revenue.
What makes Revance unique
- Revance combines DAXXIFY, Teoxane RHA fillers, SkinPen, and skincare under one platform.
- RHA Redensity Eye's August 20, 2026 FDA approval extends Revance into infraorbital rejuvenation.
- SkinPen passed one million treatment kits since January 2025, proving category leadership.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Unlimited Paid Time Off
401(k) Company Match
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↓ -1%Revance and Teoxane have received FDA approval for RHA Redensity Eye, a hyaluronic acid filler designed to treat moderate to severe undereye hollowing in adults aged 22 and older. The product delivers results lasting up to 12 months. The approval follows positive results from a 52-week US pivotal clinical study, where 93% of patients showed aesthetic improvement at three months. The study achieved 12-month results without touch-ups. RHA Redensity Eye exhibited a favourable safety profile with no late-onset or serious treatment-related adverse events. The product uses Teoxane's proprietary Preserved Network Technology, a gentle manufacturing process designed to preserve the natural structure of hyaluronic acid. RHA Redensity Eye is the first hyaluronic acid gel to demonstrate effectiveness using patient-reported outcomes as a co-primary endpoint in a US clinical study for the infraorbital region.
Revance, a global aesthetics and skincare company, has appointed Janelle Wichmann as chief marketing officer for skincare. Wichmann will report to chief executive officer Nadeem Moiz and lead the company's skincare marketing strategy, brand development and commercial growth initiatives. Wichmann brings over 15 years of leadership experience in beauty, skincare and consumer health. She previously held senior roles at Ulta Beauty and Procter & Gamble, where she helped scale Native and led a turnaround of Olay North America. Her accolades include a Cannes Silver Lion and P&G's Beauty Marketer of the Year. In her new role, Wichmann will oversee efforts to strengthen Revance's skincare portfolio and spearhead consumer skincare digital, e-commerce and loyalty initiatives. Revance's skincare brands include PanOxyl, Blue Lizard, StriVectin and others.
SkinPen milestone highlights growth in microneedling demand. 03/31/2026 Key Takeaways * Revance reported distributing more than 1 million SkinPen treatment kits since January 2025. * Growth follows the launch of SkinPen Precision Elite and reflects increasing demand for microneedling. * The company introduced a patient rebate program to support continued adoption. Revance announced that it has distributed more than 1 million SkinPen treatment kits nationwide since January 2025, marking a milestone for the company's microneedling portfolio. The achievement comes approximately 1 year after the launch of SkinPen Precision Elite, the latest iteration of the device. SkinPen is positioned as a leading microneedling platform in the United States, with the Precision Elite device designed to enhance consistency and provider control through updated balance and ergonomics. According to the company, the system builds on earlier versions of SkinPen, which are used for mechanical microneedling procedures intended to improve skin appearance with minimal downtime. "Reaching 1 million SkinPen treatment kits sold since January 2025 is a powerful proof point - not only for SkinPen, but for the rapid growth of microneedling as an in-demand aesthetic treatment," said Nadeem Moiz, Chief Executive Officer of Revance. "This momentum reflects our continued commitment to advancing the category through innovation, education, and clinically supported outcomes." To coincide with the milestone, Revance launched the "$100 Reasons to Love SkinPen" rebate program, offering patients $100 off a series of 3 or more treatments between February 1 and June 30, 2026. The company stated that the initiative is intended to support patient access and continued utilization.
Revance and Teoxane have announced the US availability of RHA Dynamic Volume, a hyaluronic acid dermal filler approved by the FDA for cheek augmentation and age-related midface contour deficiencies in adults aged 22 years or older. The product, formerly known as RHA 4 Mepi, is designed to address volume loss in both dynamic superficial fat and static deep fat, delivering results lasting up to one year. Clinical studies showed approximately 98% of patients reported natural-looking results at two months, whilst over 94% reported natural-feeling results at rest and in motion at one year. RHA Dynamic Volume uses Teoxane's unique rheology to adapt to facial movements. The launch responds to growing demand for natural-looking facial rejuvenation treatments, particularly amongst patients experiencing volume loss from weight loss medications or ageing.
Revance has launched StriVectin's Barrier Restore+ Collection, the brand's first fragrance-free line for sensitive skin. The debut includes two products: the Barrier Restore+ Soothing Ceramide Cream (£69) and Barrier Restore+ Soothing Milky Mist (£39). Both products feature a new Turmeric-146 Peptide and StriVectin's NIA-114, an optimised form of Niacin clinically proven to strengthen the skin barrier. The ceramide cream is hypoallergenic and has received the National Rosacea Society's Seal of Acceptance. In clinical testing, 90% of users reported immediate cooling and refreshment. The collection is available at Ulta stores, Ulta.com, Amazon, and StriVectin's website. StriVectin is backed by over 35 years of clinical research in skin longevity.